J&J's MedTech Unit Sales Improve in Q2: Will the Upside Continue?

Johnson & Johnson's MedTech segment, accounting for 36% of total revenues, delivered strong Q2 sales of $8.54 billion, up 7.3% year-over-year and surpassing consensus estimates, largely driven by recent acquisitions like Abiomed and Shockwave, coupled with robust performance in Cardiovascular, Surgery, and Vision. While the company anticipates sustained improvement and higher sales in the second half of 2024 due to new product momentum and easing comparables, it continues to face persistent headwinds from China's volume-based procurement program extending into 2025. J&J shares have outperformed the industry year-to-date, though its forward P/E ratio remains above the industry average.

Analysis

Johnson & Johnson's MedTech segment, which constitutes 36% of total revenue, demonstrated significant strength in the second quarter, with sales of $8.54 billion surpassing the $8.25 billion consensus estimate. This represents a 7.3% year-over-year increase, driven by 6.1% operational growth and a 1.2% positive currency impact. The performance was largely fueled by the recent acquisitions of Abiomed and Shockwave, alongside robust organic momentum in its Cardiovascular, Surgery, and Vision divisions, particularly in the United States where sales grew 8.0% operationally. Despite this strong showing, the company faces a persistent headwind from China's volume-based procurement (VBP) program, which is expected to continue impacting sales into 2025. Management remains confident in an accelerating growth trajectory for the second half of the year, citing easing comparables and the ramp-up of new products. This optimism is reflected in the market, with JNJ's stock rising 22.2% year-to-date against a 6.7% industry decline, and in analyst sentiment, as the 2025 consensus earnings estimate was recently revised upward from $10.64 to $10.86 per share. While the company's forward P/E ratio of 15.57 is higher than the industry average of 13.71, it remains slightly below its own five-year mean.

Key Decisions for Investors

• Investors should consider the strong Q2 earnings beat and positive management guidance for the second half as supportive of a continued bullish thesis, underpinned by successful acquisitions and new product cycles.
• It is critical to monitor the impact of China's volume-based procurement (VBP) program, as management has explicitly flagged this as a persistent headwind that could temper growth and margin expectations into 2025.
• While the stock's valuation is at a premium to the industry, it is in line with its historical average, suggesting that investors should assess whether the strong operational performance and growth outlook justify this multiple.
• Performance should be benchmarked against key competitors like Medtronic and Stryker to ensure J&J's growth reflects genuine market share gains rather than just broad industry trends.